US FDA expands approval to GSK’s Arexvy for adults aged 50-59, at increased risk EP News Bureau Jun 10, 2024 The RSV vaccine adjuvanted is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared…
US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults EP News Bureau May 4, 2023 Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at…
